Media.Player

IKZF1 deletions in BCR-ABL1 ALL

詳細技術說明

Investigators at St. Jude Children's Research Hospital have discovered the IKZF1 gene, which encodes the Ikaros transcription factor, is deleted in a majority of BCR-ABL1 positive acute lymphoblastic

*Abstract

Investigators at St. Jude Children's Research Hospital have discovered the IKZF1 gene, which encodes the Ikaros transcription factor, is deleted in a majority of BCR-ABL1 positive acute lymphoblastic leukemia (ALL) cases and is an acquired deletion during transformation of chronic myelogenous leukemia (CML) to ALL (lymphoid blast crisis). BCR–ABL1-positive ALL constitutes approximately 40% of adult ALL and 5% of pediatric B-progenitor ALL. The IKZF1 deletion represents the most frequently associated genetic lesion in any subtype of acute leukemia. An assay showing a deleted Ikaros protein in CML patients would suggest that monotherapy with ABL kinase inhibitors such as imatinib may be unsuccessful, and more aggressive therapy would be required. Furthermore, recent studies conducted at St. Jude show the Ikaros status is also of key prognostic importance in BCR-ABL1 negative ALL.Key words: AML and CML cancer diagnostic, Ikaros deletionGranted patents or published applications: US Publication No. 2010/0240057

國家/地區

美國